High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis
Tarun Kewalramani(Memorial Sloan Kettering Cancer Center), Craig H. Moskowitz(Memorial Sloan Kettering Cancer Center), Anna C. Priovolos(Memorial Sloan Kettering Cancer Center), Stephen D. Nimer(University of Miami), Eric Hedrick(Biogen (United States)), Gerard Donnelly(Memorial Sloan Kettering Cancer Center), Sonia Hunte(Memorial Sloan Kettering Cancer Center), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Nancy Coady Lyons(Memorial Sloan Kettering Cancer Center), Jing Qin(Memorial Sloan Kettering Cancer Center), Joachim Yahalom
Cited by 120
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k